| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Not applicable; this compound is a synthetic intermediate. Deprotected derivatives can interact with glucose transporters (GLUTs), hexokinase, and glucose-6-phosphatase. The trichloroacetimidate serves as an excellent leaving group in glycosylation reactions to synthesize glycosides, disaccharides, and oligosaccharides.
|
|---|---|
| ln Vitro |
Not directly active. Derivatives synthesized from this building block include glycosidase inhibitors (e.g., nojirimycin derivatives, IC₅0 1-100 nM), antidiabetic agents (SGLT2 inhibitors, IC₅0 1-100 nM), and anticancer agents. For glycosylation, the compound is activated with BF3·Et2O or TMSOTf (0.1-0.5 eq) in DCM at -20degC to RT.
|
| ln Vivo |
Not applicable. Used to synthesize drug candidates that are subsequently evaluated in animal models (e.g., SGLT2 inhibitors for diabetes). Not administered directly.
|
| Enzyme Assay |
Not applicable; this is a synthetic intermediate. For chemical characterization: purity by HPLC ≥98%. Appearance: white to off-white powder. Soluble in DCM, CHCl3, DMF, DMSO, THF. For glycosylation: donor (1.1-2 eq) and acceptor (1 eq) are dissolved in DCM, molecular sieves (4Angstrom) are added, and the mixture is cooled to -20degC to 0degC. TMSOTf (0.1-0.5 eq) is added, and the reaction is stirred for 1-6 h. The product is purified by column chromatography (silica). The trichloroacetimidate group can be detected by TLC (stain with sulfuric acid) and quantified by NMR (delta 8.6-8.7 ppm for NH).
|
| Cell Assay |
Not applicable; the compound is used in chemical synthesis, not in cell-based assays. If needed for cytotoxicity screening, cells can be treated with 1-100 uM compound for 48 h, and viability can be assessed by MTT. IC₅0 is expected >100 uM.
|
| Animal Protocol |
Not applicable. The building block is not administered to animals. The final drug candidates synthesized from it are studied in animal models.
|
| ADME/Pharmacokinetics |
The compound is soluble in organic solvents; insoluble in water. Not intended for direct administration. For in vitro glycosylation, it is stable in DCM at -20degC for months. Not applicable for PK.
|
| Toxicity/Toxicokinetics |
May cause skin and eye irritation. Avoid inhalation of dust. Use PPE. Low acute toxicity. Not a drug.
|
| Additional Infomation |
2,3,4,6-Tetra-O-acetyl-alpha-D-glucopyranosyl trichloroacetimidate is a research chemical intermediate for oligosaccharide synthesis. It is not a drug and has no clinical approvals. For research use only. Store at -20degC, protect from light and moisture.
|
| Molecular Formula |
C16H20CL3NO10
|
|---|---|
| Molecular Weight |
492.69
|
| Exact Mass |
491.015
|
| CAS # |
74808-10-9
|
| PubChem CID |
10896298
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.533
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
30
|
| Complexity |
695
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(=O)OCC1C(C(C(C(O1)OC(=N)C(Cl)(Cl)Cl)OC(=O)C)OC(=O)C)OC(=O)C
|
| InChi Key |
IBUZGVQIKARDAF-RKQHYHRCSA-N
|
| InChi Code |
InChI=1S/C16H20Cl3NO10/c1-6(21)25-5-10-11(26-7(2)22)12(27-8(3)23)13(28-9(4)24)14(29-10)30-15(20)16(17,18)19/h10-14,20H,5H2,1-4H3/t10-,11-,12+,13-,14-/m1/s1
|
| Chemical Name |
[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(2,2,2-trichloroethanimidoyl)oxyoxan-2-yl]methyl acetate
|
| Synonyms |
α-D-Glucopyranose, 2,3,4,6-tetraacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0297 mL | 10.1484 mL | 20.2967 mL | |
| 5 mM | 0.4059 mL | 2.0297 mL | 4.0593 mL | |
| 10 mM | 0.2030 mL | 1.0148 mL | 2.0297 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
